0001562180-21-007738.txt : 20211216 0001562180-21-007738.hdr.sgml : 20211216 20211216210436 ACCESSION NUMBER: 0001562180-21-007738 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211214 FILED AS OF DATE: 20211216 DATE AS OF CHANGE: 20211216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stock Elyse CENTRAL INDEX KEY: 0001785732 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38080 FILM NUMBER: 211499326 BUSINESS ADDRESS: BUSINESS PHONE: (203) 404-0410 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd. CENTRAL INDEX KEY: 0001689813 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-404-0410 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2021-12-14 false 0001689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN 0001785732 Stock Elyse C/O BIOHAVEN PHARMACEUTICALS, INC. 215 CHURCH STREET NEW HAVEN CT 06510 false true false false Chief Medical Officer Common Shares 2021-12-14 4 M false 3362.00 20.79 A 10829.00 D Common Shares 2021-12-14 4 M false 3577.00 10.82 A 14406.00 D Common Shares 2021-12-14 4 S false 6939.00 105.024 D 7467.00 D Common Shares 2021-12-15 4 M false 6996.00 20.79 A 14463.00 D Common Shares 2021-12-15 4 M false 14923.00 10.82 A 29386.00 D Common Shares 2021-12-15 4 S false 20330.00 105.4317 D 9056.00 D Common Shares 2021-12-15 4 S false 1589.00 106.1679 D 7467.00 D Common Shares 2187.00 I By Spouse Employee Stock Option (Right to Buy) 20.79 2021-12-14 4 M false 3362.00 0.00 D 2027-12-06 Common Shares 3362.00 18534.00 D Employee Stock Option (Right to Buy) 10.82 2021-12-14 4 M false 3577.00 0.00 D 2027-04-05 Common Shares 3577.00 14923.00 D Employee Stock Option (Right to Buy) 20.79 2021-12-15 4 M false 6996.00 0.00 D 2027-12-06 Common Shares 6996.00 11538.00 D Employee Stock Option (Right to Buy) 10.82 2021-12-15 4 M false 14923.00 0.00 D 2027-04-05 Common Shares 14923.00 0.00 D These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 - $105.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 - $105.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.00 - $106.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The shares underlying this option vested as to 25% of the shares on December 7, 2018, the grant date, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date. The shares underlying this option vested as to 25% of the shares on April 6, 2017, the grant date, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date /s/ Jim Engelhart, Attorney-in-Fact 2021-12-16